GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harpoon Therapeutics Inc (NAS:HARP) » Definitions » Goodwill-to-Asset

Harpoon Therapeutics (Harpoon Therapeutics) Goodwill-to-Asset : 0.00 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Harpoon Therapeutics Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Harpoon Therapeutics's Goodwill for the quarter that ended in Sep. 2023 was $0.00 Mil. Harpoon Therapeutics's Total Assets for the quarter that ended in Sep. 2023 was $47.58 Mil. Therefore, Harpoon Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Sep. 2023 was 0.00.


Harpoon Therapeutics Goodwill-to-Asset Historical Data

The historical data trend for Harpoon Therapeutics's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harpoon Therapeutics Goodwill-to-Asset Chart

Harpoon Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Goodwill-to-Asset
Get a 7-Day Free Trial - - - - -

Harpoon Therapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Harpoon Therapeutics's Goodwill-to-Asset

For the Biotechnology subindustry, Harpoon Therapeutics's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harpoon Therapeutics's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harpoon Therapeutics's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Harpoon Therapeutics's Goodwill-to-Asset falls into.



Harpoon Therapeutics Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Harpoon Therapeutics's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Goodwill to Asset (A: Dec. 2022 )=Goodwill/Total Assets
=0/73.729
=0.00

Harpoon Therapeutics's Goodwill to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Goodwill to Asset (Q: Sep. 2023 )=Goodwill/Total Assets
=0/47.578
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harpoon Therapeutics  (NAS:HARP) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Harpoon Therapeutics Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Harpoon Therapeutics's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Harpoon Therapeutics (Harpoon Therapeutics) Business Description

Traded in Other Exchanges
Address
131 Oyster Point Boulevard, Suite 300, South San Francisco, CA, USA, 94080
Harpoon Therapeutics Inc is a clinical-stage immunotherapy company. It is engaged in developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The company's pipeline products include HPN424, HPN536, HPN217, and others.
Executives
Vijay K Lathi 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 2500 SAND HILL ROAD, SUITE 203, MENLO PARK CA 94025
Luke Nathaniel Walker officer: Chief Medical Officer C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Frank J Lanza officer: Principal Fin. & Acctng Ofc. C/O HARPOON THERAPEUTICS, INC., 131 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Lauren P Silvernail director 15279 ALTON PARKWAY, SUITE #100, IRVINE CA 92618
Georgia Erbez officer: Chief Financial Officer 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Oncology Impact Fund (cayman) Management L.p. 10 percent owner 450 KENDALL STREET, CAMBRIDGE MA 02142
Mpm Bioventures 2014, L.p. 10 percent owner C/O MPM ASSET MANAGEMENT LLC, 450 KENDALL STREET, CAMBRIDGE MA 02142
Alan Colowick director C/O THRESHOLD PHARMACEUTICALS, INC., 1300 SEAPORT BOULEVARD, 5TH FLOOR, REDWOOD CITY CA 94063
New Leaf Bpo Associates Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
Ronald Hunt director, 10 percent owner C/O CREDIT SUISSE 1ST BOSTON PRV EQY, 11 MADISON AVENUE, NEW YORK NY 10010
New Leaf Bpo Management Ii, L.l.c 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170
New Leaf Ventures Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Associates Iii, L.p. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Venture Management Iii, L.l.c. 10 percent owner C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
New Leaf Biopharma Opportunities Ii, L.p. 10 percent owner 420 LEXINGTON AVENUE, SUITE 408, NEW YORK NY 10170

Harpoon Therapeutics (Harpoon Therapeutics) Headlines